"10.1371_journal.pmed.1001169","plos medicine","2012-02-21T00:00:00Z","Michael Delves; David Plouffe; Christian Scheurer; Stephan Meister; Sergio Wittlin; Elizabeth A Winzeler; Robert E Sinden; Didier Leroy","Department of Life Sciences, Imperial College London, London, United Kingdom; Genomics Institute of the Novartis Research Foundation, San Diego, California, United States of America; Swiss Tropical & Public Health Institute Swiss TPH, Basel, Basel, Switzerland; University of Basel, Basel, Switzerland; The Scripps Research Institute, La Jolla, California, United States of America; Medicines for Malaria Venture, Geneva, Switzerland","Conceived and designed the experiments: MD RES SW EAW. Performed the experiments: MD DP SM CS. Analyzed the data: MD CS RES SW DP EAW DL. Wrote the first draft of the manuscript: DL. Contributed to the writing of the manuscript: RES DL. ICMJE criteria for authorship read and met: MD DP CS SM SW EAW RES DL. Agree with manuscript results and conclusions: MD DP CS SM SW EAW RES DL.","EW owns Novartis stock and receives compensation from Novartis. Some of the compounds which are contained in products sold by Novartis to treat malaria (e.g., coartem) are profiled herein. DL is employed by MMV but has no influence at all on the decision for funding a project. Indeed, such a decision is taken based on the recommendations of an independent External Scientific Advisory Committee. All other authors have declared that no competing interests exist.","2012","02","Michael Delves","MD",8,FALSE,4,4,7,1,TRUE,TRUE,FALSE,0,NA,FALSE
